BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2014 2:06:00 PM | Browse: 1171 | Download: 838
 |
Received |
|
2014-01-11 12:52 |
|
Peer-Review Started |
|
2014-01-11 13:36 |
|
To Make the First Decision |
|
2014-02-13 16:02 |
|
Return for Revision |
|
2014-02-20 20:44 |
|
Revised |
|
2014-05-12 00:00 |
|
Second Decision |
|
2014-05-29 15:51 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-05-29 15:55 |
|
Articles in Press |
|
2014-05-29 16:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-07-24 14:17 |
|
Publish the Manuscript Online |
|
2014-12-11 14:23 |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Muhammad Wasif Saif, Valerie Relias, Kostas Syrigos and Krishna S Gunturu |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Muhammad Wasif Saif
Department of Medicine and Cancer Center
Tufts Medical Center
800 Washington Street Box 245
Boston, MA 02111
USA
Phone: +1-617.636.8077Fax: +1-617.636.7060
E-mail: wsaif@tuftsmedicalcenter.org
|
| Key Words |
Ziv-aflibercept; Colon cancer; Metastatic; Bleeding; Hypertension |
| Core Tip |
Ziv is an anti-angiogenic agent which has shown survival benefit in colorectal cancer. Side effects of this drug include hypertension, bleeding, perforation and delayed wound healing among others. In this paper, we review the side effects of Ziv and discuss how to manage those toxicities.We here submit a comprehensive paper on on Ziv-aflibercept (also called as zaltrap). Ziv-aflibercept (Zaltrap, Ziv),a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)- binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human immunoglobulin IgG1. As Ziv is becoming widely used in general oncology practice, it is important to understand the toxicities and to develop practice guidelines for their management.
We here provide a comprehensive review on the toxicities noted in trials using Ziv for the treatment of mCRC, and will provide recommendations for toxicity management.
We believe that this paper is of utmost importance both to the patients as well as the treating physicians.
|
| Publish Date |
2014-12-11 14:23 |
| Citation |
Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol 2014; 5(5): 1028-1035 |
| URL |
http://www.wjgnet.com/2218-4333/full/v5/i5/1028.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v5.i5.1028 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
